Optimizing frontline therapy of CLL based on clinical and biological factors.

ABSTRACT: The heterogeneity of the clinical course of chronic lymphocytic leukemia (CLL) ranges from an indolent course, where patients do not require therapy for many years, to a very aggressive disease, where treatment is required soon after diagnosis and relapses may occur early. The improved tools for prognostication allow predicting the outcome of patients with increasing reliability. Some markers also allow selecting more specific therapies with improved activity in the presence of certain genetic or clinical features of CLL. Of these markers, TP53 dysfunction, age, the presence of comorbidities and the immunoglobulin heavy-chain variable region gene mutational status, or serum markers such as β₂-microglobulin have shown independent prognostic value in multiple prospective tr

SUBMITTER: Fischer K 

PROVIDER: S-EPMC6142543 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature